Sign up to save your podcasts
Or
Share A New Normal? COVID-19 and HF in Clinical Trials
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A New Normal? COVID-19 and HF in Clinical Trials
CME credits: 0.25
Valid until: 17-09-2022
Claim your CME credit at https://reachmd.com/programs/cme/expanding-contraceptive-choices-women-vaginal-ph-modulator/12776/
The COVID-19 pandemic has had an unprecedented impact on the entire global population. COVID-19 fears have not only disrupted the regular care of patients with heart failure, but also clinical trials and their participation rates.
These studies are critical for determining the safety and efficacy of new drugs and innovative treatments. When the pandemic started, some clinical trials shut down permanently while others are finally, albeit slowly, resuming. This has created a delay in the research pipeline that may hinder how quickly new heart failure medications come to market in the next few years.
Join us as our experts—Drs. Deepak Bhatt, Javed Butler, and Giuseppe Rosano—discuss the impact of COVID-19 on patient care and the implications for clinical trial data moving forward.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 17-09-2022
Claim your CME credit at https://reachmd.com/programs/cme/expanding-contraceptive-choices-women-vaginal-ph-modulator/12776/
The COVID-19 pandemic has had an unprecedented impact on the entire global population. COVID-19 fears have not only disrupted the regular care of patients with heart failure, but also clinical trials and their participation rates.
These studies are critical for determining the safety and efficacy of new drugs and innovative treatments. When the pandemic started, some clinical trials shut down permanently while others are finally, albeit slowly, resuming. This has created a delay in the research pipeline that may hinder how quickly new heart failure medications come to market in the next few years.
Join us as our experts—Drs. Deepak Bhatt, Javed Butler, and Giuseppe Rosano—discuss the impact of COVID-19 on patient care and the implications for clinical trial data moving forward.